455 related articles for article (PubMed ID: 16549180)
1. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
[TBL] [Abstract][Full Text] [Related]
2. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
3. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
[TBL] [Abstract][Full Text] [Related]
4. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
[TBL] [Abstract][Full Text] [Related]
6. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.
Xie SB; Zhu JY; Ying Z; Zeng LJ; Chao M; Lu MQ
Transplantation; 2010 Oct; 90(7):786-90. PubMed ID: 20703179
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection.
Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V
Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081
[TBL] [Abstract][Full Text] [Related]
8. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against hepatitis B virus recurrence after liver transplantation: a registry study.
Shen S; Jiang L; Xiao GQ; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Xu MQ; Wei YG
World J Gastroenterol; 2015 Jan; 21(2):584-92. PubMed ID: 25593480
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
11. [Prevention and treatment of hepatitis B recurrence after liver transplantation].
Zhang XL; Zhu XF; Shi HJ; Cui SZ; Tang YQ; Ba MC; Wang JK; Wang B; Lu Q; Zhao HY; Wu YB; Li ML
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(9):606-9. PubMed ID: 18646715
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.
Angus PW; Patterson SJ; Strasser SI; McCaughan GW; Gane E
Hepatology; 2008 Nov; 48(5):1460-6. PubMed ID: 18925641
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of patients with lamivudine after early cessation of hepatitis B immunoglobulin for prevention of recurrent hepatitis B following liver transplantation.
Yuefeng M; Weili F; Wenxiang T; Ligang X; Guiling L; Hongwei G; Wencai L; Xiaoguang W; Wei M; Zhongyi F
Clin Transplant; 2011; 25(4):517-22. PubMed ID: 20560989
[TBL] [Abstract][Full Text] [Related]
15. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.
Akyildiz M; Karasu Z; Zeytunlu M; Aydin U; Ozacar T; Kilic M
J Gastroenterol Hepatol; 2007 Dec; 22(12):2130-4. PubMed ID: 18031370
[TBL] [Abstract][Full Text] [Related]
17. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside-Nucleotide Analog Combination Therapy Is Effective in Preventing Recurrent Hepatitis B After Liver Transplantation.
Khemichian S; Hsieh MJ; Zhang SR; Limurti J; Kim J; Fong TL
Dig Dis Sci; 2015 Sep; 60(9):2807-12. PubMed ID: 25939541
[TBL] [Abstract][Full Text] [Related]
20. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
